Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech graveyard
Biotech
Arpeggio Bio disbands after Nrf2 program starts to ‘unravel’
Arpeggio’s eight-year song has come to an end as the transcriptome biotech’s CEO admitted the company’s Nrf2 program had started to “unravel.”
James Waldron
Aug 10, 2026 5:04am
Biopharma layoffs maintain slowdown in Q1
Apr 1, 2026 8:42am
Fierce Pharma
Iterum initiates wind-down after failure to offload antibiotic
Mar 31, 2026 2:06pm
After FDA refusal, IO Biotech surrenders to bankruptcy
Mar 31, 2026 10:17am
Lipella goes bankrupt, ending mouth inflammation drug ambitions
Mar 31, 2026 7:20am
Molecular glue biotech f5 Therapeutics closes down
Mar 10, 2026 1:10pm